Form D · Pharmaceuticals

CytoDyn Inc.

Vancouver, WA · CIK 0001175680

Offering snapshot reported May 11, 2026 · SEC filing

Reported sold
$18.6M
Offering amount: $18.6M
Investors reported
194
Form D · investor count
Minimum accepted
$15K
Reported outside-investor minimum
First sale
Jan 30, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 11, 2026Initial$18,600,392No comparison194SEC filing
Sep 19, 2022Amendment$21,771,535$19,881,535vs Apr 25, 2022166SEC filing
Apr 25, 2022Amendment$1,890,000$0vs Apr 22, 202221SEC filing
Apr 22, 2022Initial$1,890,000No comparison21SEC filing
Dec 3, 2021Initial$11,361,000No comparison118SEC filing
Sep 16, 2021Initial$2,872,000No comparisonNot reportedSEC filing
Dec 16, 2020Initial$1,000,000No comparison1SEC filing
Dec 16, 2020InitialYet to sellNo comparison0SEC filing
Apr 7, 2020Amendment$7,570,000$0vs Feb 14, 20203SEC filing
Mar 30, 2020Initial$882,000No comparison1SEC filing
Feb 14, 2020Initial$7,570,000No comparison3SEC filing
Nov 12, 2019Amendment$7,788,000$4,542,000vs Apr 2, 201961SEC filing
Apr 2, 2019Initial$3,246,000No comparison53SEC filing
Sep 10, 2018Initial$13,199,385No comparison119SEC filing
Feb 28, 2018Amendment$17,643,452$16,443,552vs Nov 16, 2017200SEC filing
Nov 16, 2017Initial$1,199,900No comparison20SEC filing
Jun 14, 2017Initial$1,150,000No comparison2SEC filing
May 11, 2016Initial$4,301,500No comparison41SEC filing
Feb 23, 2016Amendment$33,268,465$31,295,965vs Jul 14, 2015261SEC filing
Oct 5, 2015Initial$2,693,800No comparison67SEC filing
Jul 14, 2015Initial$1,972,500No comparison30SEC filing
May 14, 2015Initial$3,281,050No comparison54SEC filing
Oct 29, 2013Amendment$14,500,000$11,292,740vs Sep 25, 2013170SEC filing
Sep 25, 2013Initial$3,207,260No comparison56SEC filing
Aug 5, 2013Amendment$7,788,250$1,880,000vs Feb 15, 201334SEC filing
Feb 15, 2013Amendment$5,908,250$208,250vs Oct 16, 201215SEC filing
Oct 16, 2012Initial$5,700,000No comparison14SEC filing
Sep 5, 2012Initial$575,500No comparison2SEC filing
Jan 17, 2012Initial$2,996,082No comparison86SEC filing
Aug 24, 2010InitialYet to sellNo comparison0SEC filing
Nov 19, 2009Initial$250,000No comparison1SEC filing
Oct 20, 2009InitialYet to sellNo comparison13SEC filing
May 12, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Jul 21, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$2.28M
Finders' fees
$0
Form D file number
021-583446
Excludes warrants to purchase Common Stock.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Paulson Investment Company5670

Source: Form D, filed May 11, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Allen D Allen Director, Executive
Corinne Allen Executive
Arvin Cyrus Arman Executive
Tyler Blok Executive
Karen J. Brunke Director
Karen J. Brunke, Ph.D. Director
Denis R. Burger Director
Anthony D. Caracciolo Director
Anthony D. Carraciolo Director
Arian Colachis Executive
George Dembow Director
Carl C. Dockery Director
Ryan M. Dunlap Director
Craig Eastwood Executive
Maura Fleming Executive
Gordon A. Gardiner Director
Gregory A. Gould Director
George Gould, Cpa Director
Gregory A. Gould, Cpa Director
Allan Green Director
Robert E. Hoffman Executive
Scott A. Kelly Director, Executive
Scott A Kelly, M.D. Director, Executive
Michael A. Klump Director
Jacob P. Lalezari Executive
Andrew Libby Executive
Andrew T. Libby, Jr. Executive
Antonio Migliarese Executive
Antonio Migliarese, C.P.A. Executive
Alan Bruce Montgomery Director
Michael D. Mulholland Executive
Jordan G. Naydenov Director
Lishomwa C. Ndhlovu Director
Lishomwa C. Ndhlovu, M.D., Ph.D. Director
S. Michael Nobel Director
Michael Nobel Director
Samir R. Patel, M.D. Director
Richard G. Pestell Director, Executive
Nader Z. Pourhassan Director, Executive
Nadar Z. Pourhassan Director, Executive
Nader Z Pourhassan, Ph.D Director, Executive
Nader Z. Pourhassan, Ph.D. Director, Executive
Mahboob Rahman, M.D., Ph.D. Executive
Nitya G. Ray Executive
Nitya G. Ray, Ph.D. Executive
Christopher Recknor Executive
Christopher Recknor, M.D. Executive
Harish Seethamraju Director
Stephen M. Simes Director
Alan P. Timmins Director
Richard Trauger Director, Executive
Ronald Tropp Director
Ronald J. Tropp, Esq. Director
Tanya D. Urbach Director
Kenneth Van Ness Director
David F Welch Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1111 Main Street, Suite 660
Vancouver, WA, 98660